Chimeric Designs is a protein engineering company set out to enable a safer and more effective targeted therapy for cancer. We expect that our proprietary technology will enable new treatments for a wide range of cancers.
Chimeric Designs is developing technologies that will enable specific and high capacity addition of drug-carrier conjugates exclusively to the Fc region of the antibody to overcome the fatal limitations inherent in ADCs.
We are currently designing and developing modifications to the Fc-region of antibodies that can be used to attach drug carrying cassettes site-specifically. Through this platform technology, we see the delivery of synergistic compounds that enhance drug effectiveness.
A special thanks to our partners and support from:
WSU Office of Commercialization
NSF I Corps